Literature DB >> 26186011

Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis.

Yinan Zhang1, Kevin Tianmeng Zhao1, Susan G Fox2, Jinho Kim3,4, Donald R Kirsch5, Robert J Ferrante3,4, Richard I Morimoto2, Richard B Silverman1.   

Abstract

Pyrazolone derivatives have previously been found to be inhibitors of Cu/Zn superoxide dismutase 1 (SOD1)-dependent protein aggregation, which extended survival of an amyotrophic lateral sclerosis (ALS) mouse model. On the basis of ADME analysis, we describe herein a new series of tertiary amine-containing pyrazolones and their structure-activity relationships. Further conversion to the conjugate salts greatly improved their solubility. Phosphate compound 17 exhibited numerous benefits both to cellular activity and to CNS-related drug-like properties in vitro and in vivo, including microsomal stability, tolerated toxicity, and blood-brain barrier permeation. These results indicate that tertiary amine pyrazolones comprise a valuable class of ALS drug candidates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26186011      PMCID: PMC4537347          DOI: 10.1021/acs.jmedchem.5b00561

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

Review 1.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 2.  ADMET in silico modelling: towards prediction paradise?

Authors:  Han van de Waterbeemd; Eric Gifford
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

3.  Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Authors:  Radhia Benmohamed; Anthony C Arvanites; Jinho Kim; Robert J Ferrante; Richard B Silverman; Richard I Morimoto; Donald R Kirsch
Journal:  Amyotroph Lateral Scler       Date:  2010-11-12

Review 4.  Structure-brain exposure relationships.

Authors:  Stephen A Hitchcock; Lewis D Pennington
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

Review 5.  CNS drug design: balancing physicochemical properties for optimal brain exposure.

Authors:  Zoran Rankovic
Journal:  J Med Chem       Date:  2015-01-06       Impact factor: 7.446

6.  Treatment of amyotrophic lateral sclerosis: lessons learned from many failures.

Authors:  P Hande Ozdinler; Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2014-10-08       Impact factor: 4.345

7.  Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.

Authors:  Guoyao Xia; Radhia Benmohamed; Jinho Kim; Anthony C Arvanites; Richard I Morimoto; Robert J Ferrante; Donald R Kirsch; Richard B Silverman
Journal:  J Med Chem       Date:  2011-03-04       Impact factor: 7.446

8.  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.

Authors:  Tian Chen; Radhia Benmohamed; Jinho Kim; Karen Smith; Daniel Amante; Richard I Morimoto; Donald R Kirsch; Robert J Ferrante; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-22       Impact factor: 7.446

9.  Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis.

Authors:  Yinan Zhang; Radhia Benmohamed; He Huang; Tian Chen; Cindy Voisine; Richard I Morimoto; Donald R Kirsch; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-15       Impact factor: 7.446

Review 10.  Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.

Authors:  Jeffrey D Rothstein
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

View more
  3 in total

Review 1.  Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.

Authors:  Haiyan Lu; Wei Dong Le; Ya-Ying Xie; Xiao-Ping Wang
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

2.  Polyfluoroalkylated antipyrines in Pd-catalyzed transformations.

Authors:  Evgeny V Shchegolkov; Yanina V Burgart; Daria A Matsneva; Sophia S Borisevich; Renata A Kadyrova; Iana R Orshanskaya; Vladimir V Zarubaev; Victor I Saloutin
Journal:  RSC Adv       Date:  2021-10-31       Impact factor: 4.036

Review 3.  A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.

Authors:  Georgios Pampalakis; Georgios Angelis; Eleni Zingkou; Kostas Vekrellis; Georgia Sotiropoulou
Journal:  Clin Transl Med       Date:  2022-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.